IT developer Sectra (Linköping Sweden) and Royal Philips Electronics (Amsterdam, the Netherlands) announced during the RSNA meeting an agreement to extend their partnership in PACS for another five years. As part of the alliance, Sectra provides the core
IT developer Sectra (Linköping Sweden) and Royal Philips Electronics (Amsterdam, the Netherlands) announced during the RSNA meeting an agreement to extend their partnership in PACS for another five years. As part of the alliance, Sectra provides the core image management technology used in Philips' PACS. The two companies have been working together since 1997.
Less than a week after the announcement regarding Philips, Sectra struck another agreement with Torex Health in the U.K., a leading supplier of healthcare IT in Europe. Through this partnership, Sectra's technology for handling and archiving images will be integrated with Torex's system for clinical patient information, creating a comprehensive electronic patient record that will be delivered to hospital customers in England. Torex has also agreed to sell and install Sectra systems as a strategic core component in its own overall IT solutions in the U.K and Ireland.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.